Heart failure patients mostly undiagnosed – conference

Most patients with heart failure die without the diagnosis ever being made, UK experts have claimed.

A late breaking science presentation at Heart Failure 2023, in Prague, Czechia, say this failure means patients are denied the chance to have treatments that could improve their wellbeing and reduce mortality.

Professor John Cleland of the University of Glasgow, UK, principal investigator for the study, said: “For patients with heart failure, lifestyle advice, medicines and devices can improve symptoms, reduce morbidity and prolong life but this requires someone to recognise and diagnose the condition.

“The earlier the diagnosis, the more effective treatment is likely to be. However, the results of this analysis suggest that most patients with heart failure die without the diagnosis ever being recognised.”

Many people have symptoms for years before they are diagnosed with heart failure diagnosis and it usually occurs when breathlessness and ankle swelling become severe enough to require hospitalisation.

The European Society of Cardiology (ESC) guidelines recommend loop diuretics to treat symptoms and signs of congestion due to heart failure.

However, Professor Cleland said he and colleagues noticed in an international trial of atrial fibrillation that many patients without a diagnosis of heart failure were treated with loop diuretics and that prognosis was more strongly related to the use of loop diuretics than to a diagnosis of heart failure.

“We subsequently showed similar results in an international trial of type 2 diabetes. We suspected that many patients taking loop diuretics had heart failure but it had just not been recognised,” he added.

His team examined electronic health records for about one million adults in the Greater Glasgow and Clyde area of Scotland to investigate the relationship between a diagnosis of heart failure, loop diuretic dispensing and prognosis.

The 2010-2011 baseline showed 13,000 adults (1.3%) had a diagnosis of heart failure, but 31,807 patients (3.2%) were receiving loop diuretics. Only 7,844 (25%) of those receiving loop diuretics had been diagnosed with heart failure and 70% of those taking loop diuretics without a diagnosis were women, while only 50% of those who also had a diagnosis of heart failure were women.

They were followed for five years and of those patients who were neither taking loop diuretics nor had a diagnosis of heart failure at baseline, three times more (9%) started taking loop diuretics than were diagnosed with heart failure (3%).

Few patients who were prescribed loop diuretics, predominantly by primary care physicians, were investigated for heart failure by echocardiography or by measuring natriuretic peptides.

People taking loop diuretics at baseline were more likely to be diagnosed with heart failure in the following five years (11%) than people not taking loop diuretics at baseline (3%).

After five years, about 35,000 (18%) people included in the cohort had died, with 23% of these deaths being preceded by a diagnosis of heart failure (86% also treated with loop diuretics) while 32% were preceded by initiation of loop diuretics but without a diagnosis of heart failure.

Of patients dispensed loop diuretics without a diagnosis of heart failure at baseline, 40% died during follow-up but only 11% received a new diagnosis of heart failure.

Professor Cleland concluded: “It is likely that many patients treated with loop diuretics have undiagnosed heart failure. It is also possible that inappropriate use of loop diuretics is driving adverse outcomes. Any patient treated with loop diuretics should be investigated for serious underlying heart disease, either by measuring natriuretic peptides or doing an echocardiogram or both.”

Then conference also heard from Portuguese researchers, whose study showed women are more than twice as likely to die after a heart attack than men.

A retrospective observational study, carried out by Dr Mariana Martinho of Hospital Garcia de Orta, Almada, and her team, compared short- and long-term outcomes after ST-elevation myocardial infarction (STEMI) in women and men, and examined whether any sex differences were apparent in both premenopausal (55 years and under) and postmenopausal (over 55) women.

The study included 884 patients, 27% of whom were women. Their average age was 67 compared to men, whose average was 60, and they also had higher rates of high blood pressure, diabetes and prior stroke. Men, however, were more likely to be smokers and have coronary artery disease.

At 30 days, 11.8% of women had died compared to 4.6% of men, while at five years, 32.1% of women had died compared to 16.9% of men.

The researchers conducted a further analysis of 435 patients in which they matched men and women according to risk factors for cardiovascular disease including hypertension, diabetes, high cholesterol and smoking. Adverse outcomes were then compared between matched men and women aged 55 years and under, and between matched men and women over 55 years old.

In matched patients over 55 years of age, all adverse outcomes measured were more common in women than men. Just over 11% of women died within 30 days compared with 3.0% of men and at five years, 32.9% of women had died compared with 15.8% of men.

Dr Martinho said: “The findings are another reminder of the need for greater awareness of the risks of heart disease in women. More research is required to understand why there is gender disparity in prognosis after myocardial infarction so that steps can be taken to close the gap in outcomes.”

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index